Commentary: Detection of infliximab levels and anti-infliximab antibodies

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 153-154

  Seow, C H ^a   Panaccione, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB;

ANTIBODY RESPONSE; BELGIUM; DRUG DETERMINATION; DRUG EFFECT; DRUG MONITORING; DRUG RESPONSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRANCE; GOLD STANDARD; HUMAN; IMMUNOASSAY; NETHERLANDS; NOTE; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY;

EID: 84870578795     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12107     Document Type: Note

References (11)

1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
2. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
3. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
4. Van de Casteele N, Buurman DJ, Sturkenboom MGG, et al,. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.
5. Pariente B, Pineton de Chambrun G, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
6. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y,. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-904.
7. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
8. Imaeda H, Andoh A, Fujiyama Y,. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47: 136-43.
9. Kopylov U, Mazor Y, Yavzori M, et al,. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18: 1628-33.
10. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
11. Svenson M, Geborek P, Saxne T, Bendtzen K,. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007; 46: 1828-34.